Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

productlicense right

171,727171,732515,180515,184Other

31,68027,86980,73583,283Total costs and expenses

9,955,9189,747,01329,972,72828,797,232Operating income

3,098,3602,443,8578,138,2184,264,225Interest income

52,45948,675147,628159,688Interest expense

(33,390)(547,795)(329,037)(1,299,703)Income before income taxes

3,117,4291,944,7377,956,8093,124,210Income tax expense

(1,278,472)(943,141)(3,238,421)(1,529,339)Net income

1,838,9571,001,5964,718,3881,594,871Net loss at subsidiary attributable tononcontrolling interests

8,4556,64827,80324,255Net income attributable tocommon shareholders

$
,847,412$
,008,244$
4,746,191$
,619,126Earnings per share attributable to common shareholders- basic

$
.09$
.05$
.23$
.08- diluted

$
.09$
.05$
.23$
.08Weighted-average shares outstanding- basic

20,327,53720,327,86720,414,59320,335,911- diluted

20,534,64720,803,18220,657,56721,135,762CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited)Nine Months Ended September 30,20112010Cash flows from operating activities:Net income

$
4,718,388$
,594,871Adjustments to reconcile net income to net cash flows fromoperating activities:Depreciation and amortization expense

801,483723,687Non-employee equity compensation

119,31362,547Stock-based compensation - employee stock options

467,850503,446Excess tax benefit derived from exercise of stock options

(2,657,259)(1,256,913)Non-cash interest expense

131,469328,475Net changes in assets and liabilities affectingoperating activities:Accounts receivable

640,0831,384,903Inventory

809,243(2,823,355)Other current assets and other assets

(1,240,700)1,461,538Accounts payable and other accrued liabilities

3,911,450(840,429)Other long-term obligations

(9,262)(105,668)
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
2. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
7. Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock
8. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company ... Philadelphia, PA. , The presentation took place on Tuesday, June 16 and ... the development of APX3330 for the treatment of pancreatic cancer. A copy of ...
(Date:6/30/2015)... July 1, 2015 R-Japan Co.,Ltd. obtained the license ... of Regenerative Medicine from the Ministry of Health, Labour and ... 2015. The fact that R- Japan ... the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on ... it to provide stem cell manufacturing service to medical institutions. ...
(Date:6/30/2015)... ... June 30, 2015 , ... Park Systems , ... scientific research into new classes of Nanoscale Graphene-based materials poised to revolutionize industries ... wonder material of the 21st Century' by the researchers who were awarded the ...
(Date:6/30/2015)... YORK , June 30, 2015  Today, Americord Registry, ... U.S., announced Andrew Horne , a partner at Kirkland ... Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... to Americord,s Advisory Board," says Martin Smithmyer , CEO ... in his legal career that will assist Americord,s growth and ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Americord Registry Announces Andrew Horne as Advisory Board Member 2
... ARUP Laboratories, pathologist, Ronald L. Weiss, MD, MBA, ... of American Pathologists at CAP ,11, the organization,s annual ... the CAP, the award honors members "who have made ... the specialty of pathology." (Logo: http://photos.prnewswire.com/prnh/20110915/SF69370LOGO ...
... BEACH, Fla., Nov. 9, 2011 Biotech developer Divine ... which has been expanding the topical hair-growth segment, is ... system, Polaris API Solution 9, to be supplied by ... With well-established materials like minoxidil sulfate, finasteride, alfatradiol, ...
... Nov. 9, 2011 Third Quarter Highlights ... Awarded $5.7 million contract from Department of Defense (DoD) for ... awarded PharmAthene 50% net profit split on worldwide sales of ... million in net profits Completed 1500L commercial scale-up and ...
Cached Biology Technology:ARUP Laboratories' Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology 2Divine Skin Rolls Out Polaris API Solution 9: A New Technology for Physicians 2Divine Skin Rolls Out Polaris API Solution 9: A New Technology for Physicians 3PharmAthene Reports Third Quarter 2011 Financial and Operating Results 2PharmAthene Reports Third Quarter 2011 Financial and Operating Results 3PharmAthene Reports Third Quarter 2011 Financial and Operating Results 4PharmAthene Reports Third Quarter 2011 Financial and Operating Results 5PharmAthene Reports Third Quarter 2011 Financial and Operating Results 6PharmAthene Reports Third Quarter 2011 Financial and Operating Results 7PharmAthene Reports Third Quarter 2011 Financial and Operating Results 8
(Date:6/15/2015)... -- A new report [ 1 ... US consumers using mobile banking applications want their mobile devices ... voiceprint, instead of having to prove who they are with ... Identity   -   The Fusion of Financial Services, Mobile ... primary channel used by Gen X and Gen Y to ...
(Date:6/11/2015)... , June 11, 2015 Daon, ... announced today that its IdentityX Mobile Authentication Platform ... IDentity Online) Alliance is an industry consortium launched ... standards for simpler, stronger authentication.  In order to ... pass a rigorous series of tests that measure ...
(Date:6/9/2015)... , June 09, 2015 Research ... addition of the "Gesture Recognition & Touchless ... (Consumer Electronics, Automotive, & Others), Product (Biometric & ... to 2020" report to their offering. ... market is expected to reach $ 23.55 Billion ...
Breaking Biology News(10 mins):One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... , Oct. 21, 2013   Arcturus Therapeutics, Inc. , an industry ... today announced it has secured $5 million in a Series A ... Canada , Japan and ... http://photos.prnewswire.com/prnh/20130531/MM24393LOGO ) The Series A funding, which comprised ...
... MA In a biological quirk that promises to ... potentially treating Fragile X syndrome, scientists at the University ... out a gene important for messenger RNA (mRNA) translation ... in a mouse model of a prevalent human neurological ...
... Jude Children,s Research Hospital scientists has linked an inherited ... developing a pediatric acute lymphoblastic leukemia (ALL) subtype that ... today in the online edition of the scientific journal ... found in the GATA3 gene. Researchers reported the high-risk ...
Cached Biology News:Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014 2Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014 32 genetic wrongs make a biochemical right 22 genetic wrongs make a biochemical right 32 genetic wrongs make a biochemical right 4Inherited gene variation tied to high-risk pediatric leukemia and greater risk of relapse 2Inherited gene variation tied to high-risk pediatric leukemia and greater risk of relapse 3
Request Info...
... Highly-purified, endotoxin-free plasmid DNA preparations are ... in quantities from 1mg to multi-gram ... to customer needs, and glycerol stocks ... , Transformation, clonal selection (Clonal selection ...
... plasmid DNA preparations are prepared from ... from 1mg to multi-gram scales. ... (100mg-multi-gram) preparations are made according to ... formulated according to customer needs, and ...
... The QPatch sports 16-independent channels for automated ... used for screening against voltage-gated ion channels, ... as GABA channels. The four pipette ... throughput for ion channel drug discovery. ...
Biology Products: